2-(4-异丙氧基苯基)乙胺盐酸盐 | 56370-32-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-异丙氧基苯基)乙胺盐酸盐
• 英文名称: O-Isopropyltyramin-Hydrochlorid
• 英文别名: 2-(4-isopropoxyphenyl)ethanamine hydrochloride；2-(4-Propan-2-yloxyphenyl)ethylazanium;chloride；2-(4-propan-2-yloxyphenyl)ethylazanium;chloride
• CAS: 56370-32-2
• 化学式: C₁₁H₁₇NO*ClH
• 分子量: 215.723
• InChiKey: MLEMLGGTNPFRKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-异丙氧基苯基)乙胺盐酸盐 、 二聚氰胺 以70%的产率得到
  参考文献：
  名称：

  OVSEPYAN T. R.; GEVORKYAN YU. A.; AROYAN A. A.; STEPANYAN N. S.; BUNYATYA+, AJKAKAN KIMIAKAN AMSAGIR, ARM. XIM. ZH. , 1975, 28, HO 3, 228-23+

  摘要：

  DOI：
• 作为产物：
  描述：

  2-碘代丙烷 、 4-(2-(4-methylbenzylideneamino)ethyl)phenol 在 caesium carbonate 、 盐酸 作用下， 以 甲基叔丁基醚 、 N,N-二甲基甲酰胺 、 水 、 甲苯 为溶剂， 反应 14.0h， 以92.7%的产率得到2-(4-异丙氧基苯基)乙胺盐酸盐
  参考文献：
  名称：

  Syntheses of a Selective Peroxisome Proliferator Activated Receptor Modulator and Practical New Preparations of 2-(4-Alkoxyphenyl)ethylamines

  摘要：

  This article describes chemistry that was developed to give access to multigram quantities of the selective peroxisome proliferator activated receptor modulator (SPPARM), compound 1.(1) Fischer esterifications, phase transfer-catalyzed alkylations, amide couplings, crystallizations, and a new synthesis were developed to accomplish this task. In addition, an efficient method for preparing 2-(4-alkoxyphenyl)ethylamines 7a-d from tyramine 9 was developed that involves O-alkylation of intermediate Schiff base 11 and subsequent acid-catalyzed hydrolysis to afford the target molecules as crystalline hydrochloride salts.

  DOI：

  10.1021/op800215a

文献信息

• [EN] N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG<br/>[FR] MODULATEURS N-BIPHÉNYLMÉTHYLINDOLE DE PPARG
  申请人：KAMENECKA THEODORE MARK

  公开号：WO2012170554A1

  公开（公告）日：2012-12-13

  The invention provides molecular entities that bind with high affinity to PPARG (PPARƴ), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, prediabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.